Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 42-53

  Kahlert, Ulf D ^a,c   Maciaczyk, Donata ^a   Doostkam, Soroush ^a   Orr, Brent A ^b   Simons, Brian ^b   Bogiel, Tomasz ^a   Reithmeier, Thomas ^a   Prinz, Marco ^a,c   Schubert, Jörg ^a,d   Niedermann, Gabriele ^a   Brabletz, Thomas ^a   Eberhart, Charles G ^b   Nikkhah, Guido ^a   Maciaczyk, Jaroslaw ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Novartis Pharma GmbH   (Germany)

Author keywords

Catenin; Epithelial to mesenchymal transition (EMT); Glioblastoma; Invasion; ZEB1

Indexed keywords

AXIN; AXIN 2; BETA CATENIN; CD133 ANTIGEN; DICKKOPF 1 PROTEIN; HERMES ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER INFILTRATION; CANCER INVASION; CELL COUNT; CELL MIGRATION; CELL MOTILITY; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIGENS, CD; BETA CATENIN; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLYCOPROTEINS; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PEPTIDES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84865302520     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.024     Document Type: Article

References (65)

1. Adell T., Salò E., Boutros M., Bartscherer K. Smed-Evi/Wntless is required for beta-catenin-dependent and -independent processes during planarian regeneration. Development 2009, 136:905-910.
2. Antonelli M., Buttarelli F.R., Arcella A., Nobusawa S., Donofrio V., Oghaki H., et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J. Neurooncol. 2010, 99:209-215.
3. Augustin I., Goidts V., Bongers A., Kerr G., Vollert G., Radlwimmer B., et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol. Med. 2012, 4:38-51.
4. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
5. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
6. Bleau A.-M., Huse J.T., Holland E.C. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2936-2944.
7. Brabletz T., Jung A., Hermann K., Günther K., Hohenberger W., Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 1998, 194:701-704.
8. Chamorro M.N., Schwartz D.R., Vonica A., Brivanlou A.H., Cho K.R., Varmus H.E. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J. 2005, 24:73-84.
9. Cheng W.-Y., Kandel J.J., Yamashiro D.J., Canoll P., Anastassiou D. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS ONE 2012, 7:e34705.
10. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
11. Cooper L.A.D., Kong J., Gutman D.A., Wang F., Gao J., Appin C., et al. Integrated morphologic analysis for the identification and characterization of disease subtypes. J. Am. Med. Inform. Assoc. 2012, 19:317-323.
12. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
13. DiMeo T.A., Anderson K., Phadke P., Fan C., Feng C., Perou C.M., et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69:5364-5373.
14. Dong Y.-F., Soung D.Y., Schwarz E.M., O'Keefe R.J., Drissi H. Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J. Cell. Physiol. 2006, 208:77-86.
15. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
16. Fan X., Khaki L., Zhu T.S., Soules M.E., Talsma C.E., Gul N., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
17. Firestein R., Bass A.J., Kim S.Y., Dunn I.F., Silver S.J., Guney I., et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 455:547-551.
18. Fujii N., You L., Xu Z., Uematsu K., Shan J., He B., et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007, 67:573-579.
19. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
20. Götze S., Wolter M., Reifenberger G., Müller O., Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int. J. Cancer 2010, 126:2584-2593.
21. Han S.-P., Kim J.-H., Han M.-E., Sim H.-E., Kim K.-S., Yoon S., et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell. Mol. Neurobiol. 2011, 31:489-496.
22. Izrailit J., Reedijk M. Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett. 2011.
23. Jho E., Zhang T., Domon C., Joo C.-K., Freund J.-N., Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 2002, 22:1172-1183.
24. Jin X., Jeon H.-Y., Joo K.M., Kim J.-K., Jin J., Kim S.H., et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 2011, 71:3066-3075.
25. Joost S., Almada L.L., Rohnalter V., Holz P.S., Vrabel A.M., Fernandez-Barrena M.G., et al. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res. 2011.
26. Kemler R., Hierholzer A., Kanzler B., Kuppig S., Hansen K., Taketo M.M., et al. Stabilization of beta-catenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. Development 2004, 131:5817-5824.
27. Kolligs F.T., Hu G., Dang C.V., Fearon E.R. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell. Biol. 1999, 19:5696-5706.
28. Kwon C., Cheng P., King I.N., Andersen P., Shenje L., Nigam V., et al. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol. 2011, 13:1244-1251.
29. Liu T., DeCostanzo A.J., Liu X., Wang Hy, Hallagan S., Moon R.T., et al. G protein signaling from activated rat frizzled-1 to the beta-catenin-Lef-Tcf pathway. Science 2001, 292:1718-1722.
30. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
31. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
32. Maciaczyk J., Singec I., Maciaczyk D., Klein A., Nikkhah G. Restricted spontaneous in vitro differentiation and region-specific migration of long-term expanded fetal human neural precursor cells after transplantation into the adult rat brain. Stem Cells Dev. 2009, 18:1043-1058.
33. Mikheeva S.A., Mikheev A.M., Petit A., Beyer R., Oxford R.G., Khorasani L., et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol. Cancer 2010, 9:194.
34. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
35. Nagaishi M., Paulus W., Brokinkel B., Vital A., Tanaka Y., Nakazato Y., et al. Transcriptional Factors for Epithelial-Mesenchymal Transition are Associated with Mesenchymal Differentiation in Gliosarcoma, Brain Pathology 2012, Zurich, Switzerland.
36. Nauseef J.T., Henry M.D. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?. Nat. Rev. Urol. 2011, 8:428-439.
37. Niida A., Hiroko T., Kasai M., Furukawa Y., Nakamura Y., Suzuki Y., et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004, 23:8520-8526.
38. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
39. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008, 18:523-527.
40. Orr B.A., Bai H., Odia Y., Jain D., Anders R.A., Eberhart C.G. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J. Neuropathol. Exp. Neurol. 2011, 70:568-577.
41. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
42. Pu P., Zhang Z., Kang C., Jiang R., Jia Z., Wang G., et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009, 16:351-361.
43. Pulvirenti T., Van Der Heijden M., Droms L.A., Huse J.T., Tabar V., Hall A. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res. 2011, 10.
44. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
45. Rossi M., Magnoni L., Miracco C., Mori E., Tosi P., Pirtoli L., et al. β-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol. Ther. 2011, 11:753-761.
46. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
47. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2011.
48. Sastry L., Johnson T., Hobson M.J., Smucker B., Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 2002, 9:1155-1162.
49. Scheel C., Eaton E.N., Li S.H.-J., Chaffer C.L., Reinhardt F., Kah K.-J., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
50. Schreck K.C., Taylor P., Marchionni L., Gopalakrishnan V., Bar E.E., Gaiano N., et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin. Cancer Res. 2010, 16:6060-6070.
51. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
52. Smit M.A., Peeper D.S. Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011, 30:3735-3744.
53. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J.B., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncol. 2009, 10:459-466.
54. Tabatabai G., Stupp R., van den Bent M.J., Hegi M.E., Tonn J.C., Wick W., et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010, 120:585-592.
55. Thiery J.P., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
56. Verhaak R.G.W., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
57. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
58. Wielenga V.J., Smits R., Korinek V., Smit L., Kielman M., Fodde R., et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 1999, 154:515-523.
59. Xue Y., Li L., Zhang D., Wu K., Chen Y., Zeng J., et al. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction. PLoS ONE 2011, 6:e27748.
60. Yang H.W., Menon L.G., Black P.M., Carroll R.S., Johnson M.D. SNAI2/Slug promotes growth and invasion in human gliomas. BMC Cancer 2010, 10:301.
61. Yano H., Hara A., Takenaka K., Nakatani K., Shinoda J., Shimokawa K., et al. Differential expression of beta-catenin in human glioblastoma multiforme and normal brain tissue. Neurol. Res. 2000, 22:650-656.
62. Zhang N., Wei P., Gong A., Chiu W.-T., Lee H.-T., Colman H., et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20:427-442.
63. Zhao J.-H., Luo Y., Jiang Y.-G., He D.-L., Wu C.-T. Knockdown of β-catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest. 2011, 29:377-382.
64. Zheng H., Ying H., Wiedemeyer R., Yan H., Quayle S.N., Ivanova E.V., et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010, 17:497-509.
65. Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010, 1:651-661.